GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
- Conditions
- Malaria
- Interventions
- Biological: RTS,S/AS01E vaccine
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 238
- Registration Number
- NCT07036159
- Locations
- 🇷🇼
Center for Family Health Research, Kigali, Rwanda
🇷🇼Rinda Ubuzima Gatenga Medicalized Health Center University of Rwanda, Kigali, Rwanda
A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)
- Conditions
- Meningitis
- Interventions
- Biological: rMenB+OMV NZ vaccine
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 312
- Registration Number
- NCT06995430
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
- Conditions
- Neoplasms, Prostate
- Interventions
- Drug: GSK5458514
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 82
- Registration Number
- NCT06990880
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GSK3862995BDrug: Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT06979518
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT06979323
- Locations
- 🇺🇸
GSK Investigational Site, Plantation, Florida, United States
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 960
- Registration Number
- NCT06961214
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 981
- Registration Number
- NCT06959095
- Locations
- 🇺🇸
GSK Investigational Site, Miami, Florida, United States
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT06956170
- Locations
- 🇯🇵
GSK Investigational Site, Hokkaido, Japan
🇯🇵GSK Investigation Site, Fukushima City, Fukushima-Ken, Japan
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
- First Posted Date
- 2025-04-14
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT06926673
- Locations
- 🇺🇸
GSK Investigational SIte, Nashville, Tennessee, United States
🇪🇸GSK Investigational Site, Malaga, Spain
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT06897527